In honour of Armistice / Veteran’s Day 11/11

National Harbor – We’re continuing our SITC 2019 coverage with a look at some intriguing and likely controversial data.

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15 (more on that tomorrrow)

But…

Nektar’s pegylated IL–2, bempeg, in combination with nivolumab in frontline metastatic melanoma.

The controversy will no doubt continue to rage with fervent fans and equally intense deniers, but what can we learn from the latest data that was presented by Dr Adi Diab and where are things likely headed?

Included in this latest update are an in-depth thought provoking expert interview with Nektar’s Dr Jonathan ‘JZ’ Zalevsky, plus commentary and analysis on what this all means when we look at the bigger strategic picture.

To learn more from our oncology coverage and get a heads up on our latest insights from the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by